ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

ANGO fell more than 20% after reporting a Q1 FY2027 beat, a sharp disconnect between the results and the stock's reaction.

AngioDynamics posted an adjusted loss of 4 cents per share, beating estimates by 60%. Revenues rose 6.9% year over year to $80.9 million. Med Tech revenues grew 13.2%, led by Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%.

Management reiterated FY2027 revenue guidance of $336-$341 million, with Med Tech expected to grow 12-15%. Because the company held guidance rather than raising it, the quarter delivered a beat without a change in the full-year outlook.

Interpretation: a 20%-plus drop on a clean EPS beat, a margin gain of 410 basis points, and Med Tech growth of 13.2% suggests the market wanted more than a reiteration. Med Tech's 13.2% growth sits inside the 12-15% guided range, so the quarter confirmed the existing outlook rather than exceeding it. The source does not explain the selloff, so the reasons remain speculative.

The report names no read-through for GMED, VCYT, or WST.